$SNDX
Syndax Pharmaceuticals Inc

2018 Q3 Form 10-Q Financial Statement

#000156459018026892 Filed on November 05, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $379.0K $305.0K
YoY Change 24.26% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.130M $3.560M
YoY Change 16.01% 8.87%
% of Gross Profit
Research & Development $14.10M $12.19M
YoY Change 15.65% -0.7%
% of Gross Profit
Depreciation & Amortization $150.0K
YoY Change
% of Gross Profit
Operating Expenses $18.22M $15.75M
YoY Change 15.68% 1.34%
Operating Profit -$17.84M -$15.45M
YoY Change 15.51% 1.37%
Interest Expense $488.0K $411.0K
YoY Change 18.73% 53.36%
% of Operating Profit
Other Income/Expense, Net $503.0K $358.0K
YoY Change 40.5% 33.09%
Pretax Income -$17.34M -$15.09M
YoY Change 14.91% 0.8%
Income Tax
% Of Pretax Income
Net Earnings -$17.34M -$15.09M
YoY Change 14.91% 0.79%
Net Earnings / Revenue -4574.67% -4946.89%
Basic Earnings Per Share
Diluted Earnings Per Share -$680.8K -$678.5K
COMMON SHARES
Basic Shares Outstanding 23.36M 22.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.50M $121.5M
YoY Change -24.69% 4.74%
Cash & Equivalents $26.71M $20.73M
Short-Term Investments $64.80M $100.8M
Other Short-Term Assets $4.100M $1.900M
YoY Change 115.79% 90.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $95.85M $124.0M
YoY Change -22.69% 5.72%
LONG-TERM ASSETS
Property, Plant & Equipment $396.0K $286.0K
YoY Change 38.46% 1.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $225.0K $236.0K
YoY Change -4.66% 31.84%
Total Long-Term Assets $621.0K $522.0K
YoY Change 18.97% 12.99%
TOTAL ASSETS
Total Short-Term Assets $95.85M $124.0M
Total Long-Term Assets $621.0K $522.0K
Total Assets $96.47M $124.5M
YoY Change -22.51% 5.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.180M $2.246M
YoY Change 41.59% 11.74%
Accrued Expenses $12.30M $10.70M
YoY Change 14.95% 81.36%
Deferred Revenue $1.517M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.02M $14.21M
YoY Change 19.77% 55.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $148.0K $267.0K
YoY Change -44.57% 19.73%
Total Long-Term Liabilities $15.18M $13.57M
YoY Change 11.83% -7.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.02M $14.21M
Total Long-Term Liabilities $15.18M $13.57M
Total Liabilities $32.19M $27.78M
YoY Change 15.89% 16.25%
SHAREHOLDERS EQUITY
Retained Earnings -$420.6M -$347.0M
YoY Change 21.2% 17.84%
Common Stock $2.000K $443.7M
YoY Change -100.0% 14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.27M $96.71M
YoY Change
Total Liabilities & Shareholders Equity $96.47M $124.5M
YoY Change -22.51% 5.75%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$17.34M -$15.09M
YoY Change 14.91% 0.79%
Depreciation, Depletion And Amortization $150.0K
YoY Change
Cash From Operating Activities -$18.47M -$10.18M
YoY Change 81.43% -11.09%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$40.00K
YoY Change -100.0% -20.0%
Acquisitions
YoY Change
Other Investing Activities $3.510M $6.960M
YoY Change -49.57% -14.18%
Cash From Investing Activities $3.510M $6.920M
YoY Change -49.28% -14.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.460M 1.010M
YoY Change 836.63% -40.94%
NET CHANGE
Cash From Operating Activities -18.47M -10.18M
Cash From Investing Activities 3.510M 6.920M
Cash From Financing Activities 9.460M 1.010M
Net Change In Cash -5.500M -2.250M
YoY Change 144.44% 33.14%
FREE CASH FLOW
Cash From Operating Activities -$18.47M -$10.18M
Capital Expenditures $0.00 -$40.00K
Free Cash Flow -$18.47M -$10.14M
YoY Change 82.15% -11.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26705000
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
101000
CY2018Q3 us-gaap Short Term Investments
ShortTermInvestments
62894000
CY2018Q3 us-gaap Assets
Assets
96467000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3180000
CY2018Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12319000
CY2018Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1517000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1573000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16759000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-28000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.08
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24888738
us-gaap Profit Loss
ProfitLoss
-55124000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
113012000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
94432000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18622000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35389000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24110000
us-gaap Share Based Compensation
ShareBasedCompensation
4729000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
624000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
265000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4170000
CY2018Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2017Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1138000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
915000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6146000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
95846000
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
3246000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
396000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
225000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17016000
CY2018Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
15029000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
148000
CY2018Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
15177000
CY2018Q3 us-gaap Liabilities
Liabilities
32193000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
484893000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
470571000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-35000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-420586000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
64274000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96467000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24051364
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24390033
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24390033
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
305000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11777000
us-gaap Operating Expenses
OperatingExpenses
57681000
us-gaap Operating Expenses
OperatingExpenses
43380000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15446000
us-gaap Operating Income Loss
OperatingIncomeLoss
-56543000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
379000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14095000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
488000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
503000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-17338000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17338000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
18220000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55016000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41727000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12188000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44286000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31603000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4125000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3563000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13395000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
15751000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17841000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15088000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55124000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41699000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.21
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25471587
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
411000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42465000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1422000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
959000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34649000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
173000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
39000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-9000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9584000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50108000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-53000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-193000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
358000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1419000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
766000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-15088000
us-gaap Net Income Loss
NetIncomeLoss
-55124000
us-gaap Net Income Loss
NetIncomeLoss
-41699000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22239996
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20004409
us-gaap Profit Loss
ProfitLoss
-41699000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
-282000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
233000
us-gaap Share Based Compensation
ShareBasedCompensation
4170000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2784000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
248000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
948000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-206000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1138000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-915000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
164000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4008000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53488000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
60141000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
95750000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35436000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
276000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
129000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8468000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3163000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26921000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20947000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
42000
sndx Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
59000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Syndax Pharmaceuticals, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in Delaware in 2005. We base our operations in Waltham, Massachusetts and we operate in one segment.</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:bold;"> </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. </p></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-11
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
216000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
221000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
63928000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
108391000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
38000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
143000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
63893000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
108248000
CY2018Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1925000
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1286000
CY2018Q3 us-gaap Supplies
Supplies
2106000
CY2017Q4 us-gaap Supplies
Supplies
220000
CY2018Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
254000
CY2017Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
377000
CY2018Q3 sndx Reimbursable Costs
ReimbursableCosts
1142000
CY2017Q4 sndx Reimbursable Costs
ReimbursableCosts
1029000
CY2018Q3 us-gaap Prepaid Insurance
PrepaidInsurance
379000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
192000
CY2018Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
340000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
258000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2321000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2393000
CY2018Q3 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
9043000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
91000
sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
9438000
CY2017Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
9177000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
331000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
158000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1737000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1346000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4729000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7850
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4729000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
129000
sndx Cumulative Effects Adjustment From Adoption Of New Accounting Standard
CumulativeEffectsAdjustmentFromAdoptionOfNewAccountingStandard
649000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
16780000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16780000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
sndx Tax Cuts And Jobs Act Of2017 Accounting Complete
TaxCutsAndJobsActOf2017AccountingComplete
true
CY2017Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2017Q4 sndx Tax Cuts And Jobs Act Transition Tax For Accumulated Foreign Earnings Liability
TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiability
0

Files In Submission

Name View Source Status
0001564590-18-026892-index-headers.html Edgar Link pending
0001564590-18-026892-index.html Edgar Link pending
0001564590-18-026892.txt Edgar Link pending
0001564590-18-026892-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-10q_20180930.htm Edgar Link pending
sndx-20180930.xml Edgar Link completed
sndx-20180930.xsd Edgar Link pending
sndx-20180930_cal.xml Edgar Link unprocessable
sndx-20180930_def.xml Edgar Link unprocessable
sndx-20180930_lab.xml Edgar Link unprocessable
sndx-20180930_pre.xml Edgar Link unprocessable
sndx-ex311_9.htm Edgar Link pending
sndx-ex312_8.htm Edgar Link pending
sndx-ex321_7.htm Edgar Link pending